NIPT
Ravgen NIPT Patents Withstand Illumina Challenge
The US Patent Trial and Appeal Board delivered a pair of rulings stating that Illumina failed to show Ravgen's innovations should be considered unpatentable.
The company is planning to launch a 4-in-1 prenatal screening test, a liquid biopsy test, and a minimal residual disease assay in the coming year.
The Ultra-dPCR method purports to create approximately 30 million droplets using a low-cost consumable and standard lab instruments.
ACMG Strongly Recommends NIPS for Common Trisomies for All Pregnancies
The new guidelines, based on a recent evidence review, also recommend offering NIPS for detecting fetal sex chromosome aneuploidies for singleton pregnancies.
BillionToOne Secures $83.5M in Private Funding, Loan Facility; Shows Clinical Performance of NIPT
Premium
In a recent study, pregnancy outcomes correlated with the Unity test's fetal risk estimates for recessive conditions, and the company is now conducting further validation studies.